Stuart Weisbrod and Jacob Gottlieb have reunited after almost twenty of going their separate paths. Both of the giant investors of healthcare have known each other sufficiently from the time they last worked together at the Merlin BioMed Group. They are now using the same office space while working on a collaboration for the future.
Merlin was co-founded in 1998 by Stuart Weisbrod. Merlin is a company that manages investments, primarily focusing on healthcare but also experienced in healthcare services, biotechnology, medical device, and pharmaceutical departments. With a success record in healthcare investments, Weisbrod had positions with many companies. Weisbrod has a Doctorate of Philosophy in Biochemistry, a Masters in Finance, and a Bachelors in Chemistry. Merlin closed down in 2007.
Jacob Gottlieb founded Visium Asset Management after departing from Merlin. He started with three hundred million dollars as the capital that reached two and half billion dollars by 2008. Even with the financial difficulties during 2008, Gottlieb grew his firm Visium to an eight billion dollars of borrowed invested money with nearly two hundred employees and locations in San Francisco, London, and New York.
Stuart Weisbrod founded Iguana Healthcare Partners after closing down Merlin. Akin to Merlin, Iguana’s investment focused on companies that are public within the industry of healthcare. The name Iguana came from that fact that Iguanas can emerge and survive in any environment all around the globe.
In spite of being successful for more than ten years, Visium had to close down towards the end of 2016, this was because three company executives had been accused of illegally trading stocks and fraud. This came into revelation when Jason Thorell, a whistleblower, and employee, gathered more than two years’ worth of evidence, that he presented to the FBI. Former employees were charged along with the former Chief Financial Officer. Visium has acknowledged paying almost ten million dollars for the wrongfully obtained money and fines. Gottlieb has never been charged and was pardoned of any illegal activities associated with the trading illegally scandal.
As he was closing down his frim Visium, Gottlieb started another hedge fund called Altium Capital. Through Altium, Gottlieb staked an approximate 5 and a half percent on Oramed Pharmaceuticals Incorporated. Their leading product- an insulin tablet that you take orally, replaces having to inject one’s selves with insulin. Gottlieb has taken the step to invest in this company because of its capability to transform the industry of pharmaceuticals.